The effect of obstructive jaundice on the pharmacodynamics of remazolam

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100043585

Enrollment

Unknown

Registered

2021-02-23

Start date

2021-05-01

Completion date

Unknown

Last updated

2021-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pharmacodynamics

Interventions

test group:Remazolam

Control group:Remazolam

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. patient aged 18 to 65 years; 2. The ASA classification is I-III; 3. The body mass index (BMI) is 19-27 k.m-2; 4. Test group: patients with obstructive jaundice; control group: patients with non-jaundice such as chronic cholecystitis and intrahepatic bile duct stones.

Exclusion criteria

Exclusion criteria: 1. Patients who are allergic to remazolam; 2. Long-term use of analgesics; 3. Alcoholism; 4. Nervous system or schizophrenia; 5. Advanced liver or kidney disease; 6. Sleep apnea syndrome disease; 7. Users of psychotropic drugs.

Design outcomes

Primary

Measure	Time frame
dose;	—

Countries

China

Contacts

Public ContactHUA YANG

Department of Anesthesiology, Shanghai Yangpu District Shidong Hospital

yanghuayanghua1977@163.com+86 021-25066782

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026